NuGen Medical Devices Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Ian Heynen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	1.5yrs

Recent management updates

Recent updates

CEO

Ian Heynen

less than a year

Tenure

Mr. Ian Heynen serves as CEO at NuGen Medical Devices Inc. since November 01, 2023. He serves as the Chief Financial Officer of Sentinelle Medical, Inc. Mr. Heynen has strong operating and financial leader...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Anthony Di Benedetto	Executive Chairman	1.3yrs	no data	1.08% CA$ 231.2k
Richard Buzbuzian	President & Director	1.3yrs	no data	3.37% CA$ 721.7k
Veronique Laberge	CFO & Secretary	1.2yrs	CA$90.00k	0.35% CA$ 75.0k
Nicky Canton	Executive VP & COO	no data	CA$185.68k	0.047% CA$ 10.0k
Karen Dunlap	Interim Chief Customer Officer & Director	1.4yrs	CA$11.15k	0.070% CA$ 15.0k
Ian Heynen	Chief Executive Officer	less than a year	no data	no data
Elisha Dillon	Head of Global Sales & Strategic Partnerships	2.5yrs	no data	no data

1.3yrs

Average Tenure

51yo

Average Age

Experienced Management: NGMD's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Anthony Di Benedetto	Executive Chairman	1.3yrs	no data	1.08% CA$ 231.2k
Richard Buzbuzian	President & Director	1.3yrs	no data	3.37% CA$ 721.7k
Karen Dunlap	Interim Chief Customer Officer & Director	2.6yrs	CA$11.15k	0.070% CA$ 15.0k
Christopher Irwin	Independent Director	less than a year	no data	0.21% CA$ 46.0k
Erik Emerson	Member of Advisory Board	1.6yrs	no data	no data
John Leombruno	Independent Director	2.6yrs	no data	2.47% CA$ 528.6k
Greg Gironda	Member of Advisory Board	1.7yrs	no data	no data
Philip Cortese	Independent Director	1.3yrs	no data	no data

1.5yrs

Average Tenure

51yo

Average Age

Experienced Board: NGMD's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

NuGen Medical Devices Management

Management criteria checks 0/4

Key information

Recent management updates

NuGen Medical Devices Inc. Announces Chief Executive Officer Changes

CEO, President & Director exercised options to buy CA$594k worth of stock.

Nugen Medical Devices Inc. Announces Executive Changes

Less than half of directors are independent

NuGen Medical Devices Inc. Welcomes Erik Emerson to Its Advisory Board

NuGen Medical Devices Inc. Appoints Greg Gironda to Its Advisory Board

Recent updates

Full year 2023 earnings released: CA$0.056 loss per share (vs CA$0.062 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in 3Q 2022)

NuGen Medical Devices Inc. Announces Chief Executive Officer Changes

NuGen Medical Devices Inc. Presents New Data from Preliminary Trial That Semaglutide (Ozempic ) Is Chemically Stable After It Is Administered Through Nugen 's InsuJet Needle-Free Injection Device

New major risk - Financial position

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.016 loss in 2Q 2022)

New minor risk - Insider selling

CEO, President & Director exercised options to buy CA$594k worth of stock.

First quarter 2023 earnings released: CA$0.017 loss per share (vs CA$0.017 loss in 1Q 2022)

NuGen Medical Devices Inc. announced that it has received CAD 0.45 million in funding

Full year 2022 earnings released: CA$0.062 loss per share (vs CA$0.10 loss in FY 2021)

NuGen Medical Devices Inc. announced that it has received CAD 2.5 million in funding

NuGen Medical Devices Inc. announced that it has received CAD 0.125 million in funding

Nugen Medical Devices Inc. Announces Executive Changes

NuGen Medical Devices Inc. announced that it expects to receive CAD 3 million in funding

Less than half of directors are independent

Third quarter 2022 earnings released

NuGen Medical Devices Inc. Announces the Launch of Its InsuJet Needle-Free Injection Device in Canada

NuGen Medical Devices Inc. Welcomes Erik Emerson to Its Advisory Board

NuGen Medical Devices Inc. Appoints Greg Gironda to Its Advisory Board

NuGen Medical Devices Inc. announced that it has received CAD 0.640376 million in funding

Second quarter 2022 earnings released: CA$0.016 loss per share (vs CA$0.021 loss in 2Q 2021)

NuGen Medical Devices Inc. announced that it expects to receive CAD 0.4118 million in funding

Nugen M.D. Receives Additional Health Canada Approval for Insulin Specific Needle-Free Injection System

NuGen Medical Devices Inc. Launches PetJet Providing Needle-Free Injections for Domesticated Pets

First quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.013 loss in 1Q 2021)

NuGen Medical Devices Inc., Annual General Meeting, Jun 17, 2022

Independent Director recently bought CA$53k worth of stock

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Independent Director recently bought CA$304k worth of stock

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age